Antares Pharma (AMEX:AIS), announced that Kaushik J. Dave, PhD, R.Ph., MBA, has joined Antares Pharma as Vice President of Clinical and Regulatory Affairs. Dr. Dave has over 15 years of experience in the pharmaceutical industry with both large and specialty pharma companies, directing product development from preclinical to clinical through to commercialization. His broad experience includes securing multiple product approvals from the U. S. Food and Drug Administration (FDA), European Medicines Agency (EMEA) and the Medicines Control Agency (MCA).
Prior to joining Antares Pharma Dr. Dave was employed by drug delivery companies Transave Inc. and Palatin Technologies, Inc. as well as pharmaceutical companies Schering Plough and Merck & Co. where he was responsible for IND and NDA submissions for more than 20 products. He obtained his Pharmacy degree from University of Bath, UK, a PhD in pharmaceutical chemistry from the University of Kansas, and an MBA from the Wharton School. "Antares has an excellent business plan, a cutting-edge technology platform and a robust pipeline. I welcome the opportunity to be part of the team that is integrating these key strengths for the purpose of creating novel products," said Dr. Dave. "I look forward to making a contribution to Antares as well as to patients who may benefit from the products that we bring to the market."
“We are very pleased to have Dr. Dave join our management team at this juncture; he brings a wealth of clinical and regulatory expertise to lead our clinical development program. Presently we are enrolling patients in our pivotal trials for ANTUROL™ ATD™ (Advanced Transdermal Gel Delivery System) for the treatment of overactive bladder. We are also initiating a clinical program for our proprietary CNS (ATD gel) product, AP-1126. Additionally, we are planning a Phase II trial with the Population Council for our Nestorone®/estradiol ATD gel contraceptive, to commence later this year. The progress of our clinical program demonstrates our advancement toward becoming a principal specialty pharma company,” commented Jack E. Stover, President and CEO.
About Antares Pharma
Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated drug delivery platforms: the ATDTM Advanced Transdermal Delivery system, subcutaneous injection technology platforms including both VibexTM disposable mini-needle injection device and ValeoTM/Vision® reusable needle-free injection devices; and Easy TecTM oral fast-melt technology. Two of the platforms have generated FDA approved products. Antares Pharma leverages its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. The Company’s products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Safe Harbor Statement
This press release contains forward-looking statements, within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the “Risk Factors” section of Antares’ Annual Report on Form 10-K for the year ended December 31, 2006 and in Antares’ periodic reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Antares is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. Forward-looking statements, including statements regarding the timing of product sales, market estimates and market potential provide Antares' current expectation or forecasts of future events. Antares' results could differ materially from those reflected in these forward-looking statements due to decisions of regulatory authorities, Antares' ability to execute on its development plans and general financial, economic, regulatory and political conditions affecting the pharmaceutical industry generally.